hotspot -WSS

hotspot

author：focus 2025-09-30 12:18:45 - browse：833

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Tuskegee Airman Raymond Cassagnol dies at 102

WSS

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Former medical device CEO who sold dummy, plastic parts convicted of fraud

The strange history of BMI, the body mass index

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

NEJM study link tiny plastics in blood vessels to heart problems

RSV shot was 90% effective at preventing hospitalizations in kids

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Amylyx ALS drug failure raises questions and concerns

State Dept. review finds Biden bears some blame for Afghanistan failures

The Readout: Amylyx, Alumis, and Lundbeck drug updates

In Memoriam: Notable people who died in 2023

Eating disorder hotline's move to chatbot carried cost for volunteers

Duchenne breakthrough therapy leaves behind pioneering families

Supreme Court strikes down Biden student loan forgiveness program

Affirmative action in medical school literally saved lives

With psoriasis trial ahead, Alumis raises $259 million

hotspot

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Amylyx ALS drug failure raises questions and concerns

Former medical device CEO who sold dummy, plastic parts convicted of fraud

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Change Healthcare payments predicted restored March 15

First medicine developed to treat MASH expected to be approved soon

focus

focus

focus

explore